{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:55:36Z","timestamp":1790384136375,"version":"4.1.0"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2018,12,7]],"date-time":"2018-12-07T00:00:00Z","timestamp":1544140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"CIHR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Canadian Foundation for Innovation (CFI)"},{"name":"Bristol-Myers-Squibb"},{"name":"La Fondation Pierre Deniker"},{"name":"Toulouse University Hospital"},{"name":"CHU Toulouse"},{"name":"Fonds de recherche du Qu\u00e9bec \u2013 Sant\u00e9"},{"name":"William Dawson Scholar award"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess whether abatacept as initial biological DMARD (bDMARD) in the treatment of RA, when compared with other bDMARDs, is associated with an increased risk of cancer overall and by specific cancer sites (breast, lung, lymphoma, melanoma and non-melanoma skin cancer).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a population-based cohort study among patients newly treated with bDMARDs within the US-based Truven MarketScan population and Supplemental US Medicare from 2007 to 2014. Cox proportional hazards models were used to estimate hazard ratios and 95% CIs of any cancer (and specific cancers) associated with initiation of abatacept, compared with initiation of other bDMARDs, adjusted for age and deciles of the propensity score.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The cohort included 4328 patients on abatacept and 59 860 on other bDMARDs, of whom 409 and 4197 were diagnosed with any cancer during follow-up (incidence rates 4.76 per 100 per year and 3.41 per 100 per year, respectively). Compared with other bDMARDs, the use of abatacept was associated with an increased incidence of cancer overall (hazard ratioadjusted 1.17; 95% CI 1.06, 1.30). Analyses by specific cancer sites showed a significantly increased incidence of non-melanoma skin cancer (hazard ratioadjusted 1.20; 95% CI 1.03, 1.39), but no significant difference for other specific cancer sites.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The use of abatacept as first bDMARD in the treatment of RA was associated with a slight increased risk of cancer overall and particularly non-melanoma skin cancer, compared with other bDMARDs. This potential signal needs to be replicated in other settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/key352","type":"journal-article","created":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T02:55:46Z","timestamp":1540263346000},"page":"683-691","source":"Crossref","is-referenced-by-count":68,"title":["Abatacept initiation in rheumatoid arthritis and the risk of cancer: a population-based comparative cohort study"],"prefix":"10.1093","volume":"58","author":[{"given":"Fran\u00e7ois","family":"Montastruc","sequence":"first","affiliation":[{"name":"Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montr\u00e9al, Qu\u00e9bec, Canada"},{"name":"Service de Pharmacologie M\u00e9dicale et Clinique, Centre de PharmacoVigilance, de Pharmaco\u00e9pid\u00e9miologie et d'Informations sur le M\u00e9dicament de Toulouse, Facult\u00e9 de M\u00e9decine, Centre Hospitalier Universitaire, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christel","family":"Renoux","sequence":"additional","affiliation":[{"name":"Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montr\u00e9al, Qu\u00e9bec, Canada"},{"name":"Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montr\u00e9al, Qu\u00e9bec, Canada"},{"name":"Department of Neurology and Neurosurgery, McGill University, Montr\u00e9al, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Dell\u2019Aniello","sequence":"additional","affiliation":[{"name":"Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montr\u00e9al, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa A","family":"Simon","sequence":"additional","affiliation":[{"name":"Global Pharmacovigilance and Epidemiology Bristol Myers Squibb, Hopewell, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Azoulay","sequence":"additional","affiliation":[{"name":"Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montr\u00e9al, Qu\u00e9bec, Canada"},{"name":"Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montr\u00e9al, Qu\u00e9bec, Canada"},{"name":"Gerald Bronfman Department of Oncology, McGill University, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Hudson","sequence":"additional","affiliation":[{"name":"Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montr\u00e9al, Qu\u00e9bec, Canada"},{"name":"Division of Rheumatology, Lady Davis Institute, Jewish General Hospital, Montr\u00e9al, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1281-5296","authenticated-orcid":false,"given":"Samy","family":"Suissa","sequence":"additional","affiliation":[{"name":"Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montr\u00e9al, Qu\u00e9bec, Canada"},{"name":"Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montr\u00e9al, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,12,7]]},"reference":[{"key":"2019081609503244800_key352-B1","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1742-7843.2009.00375.x","article-title":"Abatacept, a novel CD80\/86-CD28 T cell co-stimulation modulator, in the treatment of rheumatoid arthritis","volume":"104","author":"Korhonen","year":"2009","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2019081609503244800_key352-B2","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s40265-017-0775-4","article-title":"Abatacept: a review in rheumatoid arthritis","volume":"77","author":"Blair","year":"2017","journal-title":"Drugs"},{"key":"2019081609503244800_key352-B3","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1136\/ard.2007.085852","article-title":"Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register","volume":"68","author":"Askling","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2019081609503244800_key352-B4","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1136\/annrheumdis-2011-200622","article-title":"The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register","volume":"71","author":"Mercer","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2019081609503244800_key352-B5","doi-asserted-by":"crossref","first-page":"f1939","DOI":"10.1136\/bmj.f1939","article-title":"Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden","volume":"346","author":"Raaschou","year":"2013","journal-title":"BMJ"},{"key":"2019081609503244800_key352-B6","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/fcp.12171","article-title":"Tumor necrosis factor inhibitors added to nonbiological immunosuppressants vs. nonbiological immunosuppressants alone: a different signal of cancer risk according to the condition. A disproportionality analysis in a nationwide pharmacovigilance database","volume":"30","author":"Saliba","year":"2016","journal-title":"Fundam Clin Pharmacol"},{"key":"2019081609503244800_key352-B7","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jamadermatol.2015.3029","article-title":"Risk of nonmelanoma skin cancer associated with the use of immunosuppressant and biologic agents in patients with a history of autoimmune disease and nonmelanoma skin cancer","volume":"152","author":"Scott","year":"2016","journal-title":"JAMA Dermatol"},{"key":"2019081609503244800_key352-B8","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.semarthrit.2013.08.003","article-title":"Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs","volume":"43","author":"Solomon","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"2019081609503244800_key352-B9","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1001\/jamainternmed.2017.4332","article-title":"Malignant neoplasms in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, tocilizumab, abatacept, or rituximab in clinical practice: a Nationwide Cohort Study from Sweden","volume":"177","author":"Wadstr\u00f6m","year":"2017","journal-title":"JAMA Intern Med"},{"key":"2019081609503244800_key352-B10","first-page":"401","article-title":"Factors associated with the initiation of biologic disease-modifying antirheumatic drugs in Texas Medicaid patients with rheumatoid arthritis","volume":"21","author":"Kim","year":"2015","journal-title":"J Manag Care Spec Pharm"},{"key":"2019081609503244800_key352-B11","first-page":"409","article-title":"Comparative efficacy of novel DMARDs as monotherapy and in combination with methotrexate in rheumatoid arthritis patients with inadequate response to conventional DMARDs: a network meta-analysis","volume":"21","author":"Buckley","year":"2015","journal-title":"J Manag Care Spec Pharm"},{"key":"2019081609503244800_key352-B12","year":"2017"},{"key":"2019081609503244800_key352-B13","first-page":"106","article-title":"Positive predictive value (PPV) of an administrative data-based algorithm for the identification of patients with rheumatoid arthritis (RA","volume":"44","author":"MacLean","year":"2001","journal-title":"Arthritis Rheum"},{"key":"2019081609503244800_key352-B14","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3899\/jrheum.140853","article-title":"Rates of serious infections and malignancies among patients with rheumatoid arthritis receiving either tumor necrosis factor inhibitor or rituximab therapy","volume":"42","author":"Aaltonen","year":"2015","journal-title":"J Rheumatol"},{"key":"2019081609503244800_key352-B15","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.jbspin.2010.11.012","article-title":"Rituximab in rheumatoid arthritis and the risk of malignancies: report from a French cohort","volume":"78","author":"Slimani","year":"2011","journal-title":"Joint Bone Spine"},{"key":"2019081609503244800_key352-B16"},{"key":"2019081609503244800_key352-B17","year":"2017"},{"key":"2019081609503244800_key352-B18","doi-asserted-by":"crossref","first-page":"e178","DOI":"10.1016\/j.jaad.2013.04.018","article-title":"Eruptive squamous cell carcinoma in a patient receiving abatacept for rheumatoid arthritis","volume":"69","author":"Corcorran","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"2019081609503244800_key352-B19","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.intimp.2016.05.016","article-title":"The role of CTLA-4 and PD-1 in anti-tumor immune response and their potential efficacy against osteosarcoma","volume":"38","author":"Wang","year":"2016","journal-title":"Int Immunopharmacol"},{"key":"2019081609503244800_key352-B20","doi-asserted-by":"crossref","first-page":"42913","DOI":"10.1038\/srep42913","article-title":"The prognostic value of cytotoxic T-lymphocyte antigen 4 in cancers: a systematic review and meta-analysis","volume":"7","author":"Hu","year":"2017","journal-title":"Sci Rep"},{"key":"2019081609503244800_key352-B21","year":"2017"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/58\/4\/683\/28720250\/key352.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T04:20:41Z","timestamp":1589948441000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/58\/4\/683\/5232676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,7]]},"references-count":21,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,12,7]]},"published-print":{"date-parts":[[2019,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/key352","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,4]]},"published":{"date-parts":[[2018,12,7]]}}}